Clinical trial

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

NCT04530227

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Biological: Camrelizumab Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pemetrexed Normalized identity: pemetrexedView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Nab-paclitaxel Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2020-09-25

PhasePHASE2

Conditions

Early Stage Non-small Cell Lung Cancerunresolved

Interventions

Biological: CamrelizumabDRUG

PemetrexedDRUG · verified · RxNorm: pemetrexed

Nab-paclitaxelDRUG

Sponsors & collaborators

Tianjin Medical University Cancer Institute and Hospitallead sponsor

Mapped research locations

TianjinChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04530227 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.